Clinuvel Pharmaceuticals Limited's market cap is currently $566.69M. The company's EPS TTM is AU$0.711; its P/E ratio is 15.83; and it has a dividend yield of 0.45%. Clinuvel Pharmaceuticals Limited is scheduled to report earnings on February 25, 2025, and the estimated EPS forecast is AU$0.22. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
Income Statement
Total Revenue	AU$ 88.18M	AU$ 78.32M	AU$ 65.72M	AU$ 47.98M	AU$ 32.57M
Gross Profit	AU$ 80.45M	AU$ 50.59M	AU$ 46.62M	AU$ 35.20M	AU$ 18.43M
Operating Income	AU$ 49.15M	AU$ 40.91M	AU$ 33.08M	AU$ 26.70M	AU$ 10.20M
EBITDA	AU$ 56.28M	AU$ 46.37M	AU$ 35.08M	AU$ 26.57M	AU$ 11.99M
Net Income	AU$ 35.64M	AU$ 30.60M	AU$ 20.88M	AU$ 24.73M	AU$ 16.65M
Balance Sheet
Cash & Short-Term Investments	AU$ 183.87M	AU$ 156.81M	AU$ 121.51M	AU$ 82.69M	AU$ 66.75M
Total Assets	AU$ 231.12M	AU$ 194.52M	AU$ 144.81M	AU$ 108.57M	AU$ 81.54M
Total Debt	AU$ 879.78K	AU$ 999.87K	AU$ 1.26M	AU$ 1.30M	AU$ 1.32M
Net Debt	AU$ -182.99M	AU$ -22.87M	AU$ -26.15M	AU$ -35.84M	AU$ -24.33M
Total Liabilities	AU$ 28.11M	AU$ 29.89M	AU$ 19.25M	AU$ 9.83M	AU$ 9.48M
Stockholders' Equity	AU$ 203.01M	AU$ 164.63M	AU$ 125.56M	AU$ 98.74M	AU$ 72.07M
Cash Flow
Free Cash Flow	AU$ 31.48M	AU$ 35.88M	AU$ 39.44M	AU$ 18.41M	AU$ 13.30M
Operating Cash Flow	AU$ 37.05M	AU$ 36.91M	AU$ 39.87M	AU$ 19.26M	AU$ 14.19M
Investing Cash Flow	AU$ -29.03M	AU$ -1.03M	AU$ -434.44K	AU$ -854.33K	AU$ -888.83K
Financing Cash Flow	AU$ -3.57M	AU$ -2.24M	AU$ -1.50M	AU$ -1.48M	AU$ -1.49M

Currency in AUD

Clinuvel Pharmaceuticals Limited Earnings and Revenue History

Income Statement >

Clinuvel Pharmaceuticals Limited Debt to Assets

Balance Sheet >

Clinuvel Pharmaceuticals Limited Cash Flow

Cash Flow >

Clinuvel Pharmaceuticals Limited Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing